Figure 2From: Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment A. Effects of ZOL and docetaxel treatments on bone volume. Bone volume as a percentage of the total volume was determined by bone histomorphometrical analysis. The ZOL + docetaxel treatment significantly increased bone volume compared to that of the control group (p = 0.0164, *). %BV/TV of the ZOL group was increased in comparison to the control group but the changes did not reach significance (p = 0.0839). B. Effects of ZOL and docetaxel treatments on serum PSA levels. Blood was drawn weekly from each treatment group, control (■), ZOL (●), Docetaxel (▼), or ZOL + docetaxel (○), and analyzed for PSA levels (ng/ml). The combination of ZOL + docetaxel decreased PSA levels significantly compared to those in the control animals. C. Effects of ZOL and docetaxel treatments on tumor volume. Tumor volume as a percentage of the total volume was determined by bone histomorphometrical analysis for the four treatment groups. The ZOL and ZOL + docetaxel treatments decreased tumor volume significantly (p = 0.027, 0.0002, respectively *) compared to that of the control group. The combination of ZOL and docetaxel resulted in decreased tumor volume in comparison to animals receiving ZOL alone; however, these results did not reach significance (p = 0.111).Back to article page